UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

					SEC File Number: 000-21846 CUSIP Number: 00808Y109
(CHECK ONE):	☐ Form 10-K ☐ Form N-SAR For Period Ended: March 31, 2010 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended:	☐ Form 20-F ☐ Form N-CSR	□ Form 11-K	□Form 10-Q	□ Form 10-D
		10,0	1 0	- 1	
	Nothing in this form shall			erified any information	
If the notification	n relates to a portion of the filing checked above	e, identify the Item(s) to v	which the notification relates	: N/A	
PART I - REGI	STRANT INFORMATION				
Aethlon Medica					
Full Name of Re	gistrant				
Bishop Equities					
Former Name if	Applicable				
8910 University	Center Lane, Suite 660				
Address of Princ	ipal Executive Office (Street and Number)				
San Diego, Cali	fornia 92122				
City, State and Z			CUSIP Number: 00808Y109 1 20-F		
PART II - RUL	ES 12b-25 (b) AND (c)				
If the subject rep box if appropriat		ort or expense and the reg	istrant seeks relief pursuant	to Rule 12b-25(b), the foll	owing should be completed. (Check
(a) (b)	The subject annual report, semi-annual report, be filed on or before the fifteenth calendar da distribution report on Form 10-D, or portion the	transition report on For y following the prescribe ereof, will be filed on or	m 10-K, Form 20-F, Form 1 ed due date; or the subject of before the fifth calendar day	1-K, Form N-SAR or For quarterly report or transition y following the prescribed	m N-CSR, or portion thereof, will on report on Form 10-Q or subject

PART III - NARRATIVE

State below in reasonable detail why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Due to the necessity of obtaining a third party valuation on a note restructuring, the start of the fieldwork by our independent auditor was delayed, which has delayed completion of the financial statements.

PART IV - OTHER INFORMATION

(1)	Name and telephone number of person to contact in regard to this no	Name and telephone number of person to contact in regard to this notification						
	James A. Joyce	(858)	459-7800					
	(Name)	(Area Code)	(Telephone Number)					
(2)	Have all other periodic reports required under Section 13 or 15(d) of the preceding 12 months or for such shorter period that the registran	_	1 ,					
(3)	Is it anticipated that any significant change in results of operations fi included in the subject report or portion thereof?	rom the corresponding period for the last f	iscal year will be reflected by the earnings statements to be ☐ Yes ☑ No					
If so, made.	attach an explanation of the anticipated change, both narratively and q	quantitatively, and, if appropriate, state the	reasons why a reasonable estimate of the results cannot be					
		Aethlon Medical, Inc.						
has ca	nused this notification to be signed on its behalf by the undersigned here	eunto duly authorized.						
Date:	June 29, 2010	/s/ James A. Joyce						
		James A. Joyce, Chief Execu	James A. Joyce, Chief Executive Officer					
form :	RUCTION: The form may be signed by an executive officer of the reshall be typed or printed beneath the signature. If the statement is signed representative's authority to sign on behalf of the registrant shall be file.	d on behalf of the registrant by an authorize						
		ATTENTION						
	Intentional misstatements or omissions of	f fact constitute Federal Criminal Viola	tions (See 18 U.S.C. 1001).					